Comparing 11 approaches for non-small-cell lung carcinoma

Exclusion

• −Previously had a severe hypersensitivity reaction to treatment with monoclonal antibodies (including pembrolizumab) and/or any of their excipients
• −Has a known history of human immunodeficiency virus (HIV) infection. Well-controlled HIV with anti-retroviral therapy (ART) is not excluded
• −Has a known history of Hepatitis B (HPV) or known active Hepatitis C virus infection. Hepatitis B surface antigen (HBsAg) positive is eligible if on HBV antiviral therapy for at least 4 weeks and HBV viral load is undetectable prior to randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more →
• −The main exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → include but are not limited to the following:
• −Has a diagnosis of small cell lung cancer
• −Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment
• −Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
• −Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• −Has an active autoimmune disease that has required systemic treatment in the past 2 years
• −Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
• −Has an active infection requiring systemic therapy
• −Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study treatment administration, or New York Heart Association Class III or IV congestive heart failure
• −Is expected to require any other form of antineoplastic therapy while on study
• −Has a history or current evidence of a gastrointestinal (GI) condition (e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver function or diseases that in the opinion of the investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more → may significantly alter the absorption or metabolism of oral medications
• −Has preexisting neuropathy that is moderate in intensity
• −Is unable or unwilling to take folic acid or vitamin B12 supplementation, for participants who will receive pemetrexed
• −Has a known sensitivity to any component of carboplatin, paclitaxel, pemetrexed or any of their excipients
• −Has received a live vaccine within 30 days before the first dose of study treatment. Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed as long as they are messenger ribonucleic acid (mRNA) vaccines, adenoviral vaccines, or inactivated vaccines. Investigational vaccines (ie, those not licensed or approved for Emergency Use) are not allowed
• −Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study treatment
• −Has had an allogenic tissue/solid organ transplant
• −Has had major surgery \<3 weeks before the first dose of study treatment
• −Is getting chemotherapy and has clinically active diverticulitis, intra-abdominal abscess, GI obstruction, or peritoneal carcinomatosis
• −Has received prior systemic cytotoxic chemotherapy or other targeted or biological antineoplastic therapy for metastatic disease
• −Has received prior radiation therapy to the lung that is \>30 Gray (Gy) within 6 months of the first dose of study treatment
• −Has received any prior immunotherapy and was discontinued from that treatment due to a severe or worse immune-related adverse eventAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more → (irAE)
• −Has had chemotherapy or biological cancer therapy within 4 weeks before the first dose of study treatment or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from the AEs due to cancer therapeutics administered more than 4 weeks before the first dose of study treatment (including participants who had previous immunomodulatory therapy with residual irAEs)